Veeda and Somru announced the launch of their premier global centre of excellence lab under the flagship of Ingenuity BioSciences Pvt. Ltd.
The board of directors of both companies have made a strategic alliance to expand their specialized service offerings, complementing their well-established portfolio in clinical services and bioassay kit development.
This collaborative joint venture aims to capture the growing market needs of the global biosimilars market.
Somru BioScience and Veeda Clinical Research will have an equal partnership in the new joint venture.
Ingenuity BioSciences will be established as a premier and agile bioanalytical laboratory. Somru BioScience's proprietary automation platform and cloud based Aegryris bioanalytical and productivity software suite will be a potential game-changer in the innovation-based drug discovery industry.
Ingenuity BioSciences aims to offer end-to-end and modular technical services, encompassing both pre-clinical and clinical domains.
The Ingenuity BioSciences scientific team is comprised of talented scientists with in-depth and extensive knowledge of bioassay method development and sample analysis, clinical trial management, and global regulatory requirements.
Business development and technical teams are enthusiastic and excited to collaborate and serve Indian and International clients across pan-Asia and European markets.
Ingenuity BioSciences' website will be soon available and provide detailed information on service offerings.
Ingenuity BioSciences will be led by Mohammed Moin, CEO of Somru BioScience and Dr. Ravi Krovidi, CEO of Ingenuity BioSciences Pvt Ltd.
The location of Ingenuity BioSciences in Ahmedabad, India, gives its clients a unique advantage of sharing the years of trust, regulatory expertise and reputation established by the Veeda Clinical Research services ecosystem.
Somru Bioscience Inc. is an innovative biotechnology company based out of Prince Edward Island, Canada.
Somru has developed a portfolio of reagents, ELISA kits, innovative biosimilar comparability tools and a cloud based Aegryris software suite to enable companies to significantly reduce the cost and timeline for biosimilar development.
Somru technologies reduce early development risk by identifying clinically meaningful differences prior to running expensive clinical trials.
The company has customers throughout North and South America, Europe, Australia, and Asia.
Veeda is a independent Clinical Research Organization in India conducting a diverse range of clinical studies including bioavailability and bioequivalence (BA/BE) studies, pharmacokinetics, pharmacodynamics, early to late phase clinical development and clinical endpoint studies for generic molecules, new chemical entities, and biopharmaceuticals.
Veeda strives for excellence in quality and has been the partner of choice for many global pharmaceutical companies over the last 16 years.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling